DNAnexus, a leader in enterprise platforms for precision health data, has strengthened its executive team with the appointments of Pieter De Leenheer, PhD, as Chief Technology Officer and Todd Oakland, PhD, as Senior Vice President and General Manager of the Biopharma Business Dx/Rx. The moves underscore the company’s strategic focus on advancing AI-driven innovation and expanding its footprint in the biopharmaceutical sector. Thomas Laur, CEO of DNAnexus, expressed enthusiasm about the new leadership, highlighting their proven track records in scaling enterprise software and driving product innovation in healthcare and life sciences. “Their expertise will be instrumental in accelerating our AI and platform strategies as we grow our biopharma business and advance precision health for everyone,” Laur said. Dr. Pieter De Leenheer brings over two decades of experience in data-driven technology and enterprise software. Most recently, he served as CTO at 1upHealth and ZenOptics, and co-founded Collibra, a global data intelligence platform that grew to serve over 500 enterprise clients and raised more than $600 million. He holds a PhD in computer science and artificial intelligence from Vrije Universiteit Brussels and has held academic roles at Harvard Business School, Columbia University, and the San Diego Supercomputer Center. He currently advises the European Commission on data and AI policy. Dr. De Leenheer will lead DNAnexus’s technology vision, focusing on scaling platform capabilities to manage peta-scale, multimodal clinico-genomic data. Dr. Todd Oakland joins DNAnexus from ConcertAI, where he led product development for precision oncology solutions, delivering AI-powered SaaS and real-world evidence platforms to pharmaceutical and diagnostic organizations. Prior to that, he held leadership roles at Aitia and GNS Healthcare, focusing on advanced analytics and real-world data applications. With a PhD in virology from the University of Chicago, an MPH in quantitative methods from Harvard, and a BS in molecular biology from Purdue University, Dr. Oakland brings deep scientific and product leadership experience. He will lead the biopharma business, driving solutions that help pharmaceutical partners navigate complex data environments and accelerate drug development. In addition, George Asimenos, PhD, has transitioned from Chief AI Officer to Chief Product Officer, where he will shape the strategic direction of the DNAnexus platform. This shift reflects the company’s continued commitment to integrating AI into its core offerings. DNAnexus currently supports over 60,000 users across 48 countries and manages more than 125 petabytes of clinical, genomic, proteomic, and multiomic data. The company’s platform meets the highest standards for data security, privacy, and regulatory compliance. It recently launched the GenAI-powered Omics Data Assistant in early access, designed to help non-technical users accelerate discovery through intuitive AI tools. DNAnexus is on a mission to accelerate personalized medicine by making precision health data accessible, secure, and actionable. The company’s platform powers a connected ecosystem trusted by leading organizations in research, biopharma, and healthcare. For more information, visit www.dnanexus.com or follow @DNAnexus on social media.